TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,226,051 | +20.3% | 2,150,565 | +106.7% | 0.22% | +19.0% |
| Q2 2023 | $15,978,947 | -50.7% | 1,040,296 | -27.7% | 0.19% | -57.1% |
| Q1 2023 | $32,378,831 | +1488.8% | 1,439,699 | +1385.6% | 0.44% | +1533.3% |
| Q4 2022 | $2,037,975 | -69.2% | 96,908 | -63.9% | 0.03% | -70.7% |
| Q3 2022 | $6,608,000 | +86.7% | 268,175 | +83.8% | 0.09% | +58.6% |
| Q3 2021 | $3,539,000 | – | 145,918 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |